Dual Incretin Receptor Mechanism
The incretin system consists of two principal gut-derived hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both are released from enteroendocrine cells in response to nutrient ingestion and potentiate glucose-stimulated insulin secretion from pancreatic beta cells. Until tirzepatide, GIP had been largely characterised as the "forgotten incretin" — its receptor was known to mediate insulin secretion, but early pharmacological investigations with GIPR antagonists showed modest metabolic effects, leading researchers to underestimate its therapeutic potential. Tirzepatide has fundamentally rehabilitated this view.
Unlike native GIP, tirzepatide acts as a biased agonist at the GIPR: it selectively engages cAMP-dependent signalling pathways whilst producing attenuated receptor internalisation relative to native GIP. This biased engagement appears critical to its in vivo efficacy, as it sustains downstream insulin-potentiating and appetite-modulating effects without the receptor downregulation that might blunt a prolonged pharmacological response. Critically, tirzepatide does not simply stack two independent incretin signals — the interaction between GIPR and GLP-1R signalling is genuinely synergistic, with dual activation producing metabolic outcomes that exceed the arithmetic sum of each receptor's individual contribution.
The Rehabilitation of GIP: From Forgotten Incretin to Therapeutic Target
For decades, the GIP receptor was considered a suboptimal drug target. Selective GIPR agonists administered alone to obese subjects showed minimal weight-loss effect, and some rodent models suggested GIPR antagonism might even be beneficial in obesity — a seemingly paradoxical finding. This led many researchers to focus exclusively on GLP-1R as the relevant incretin pathway.
Tirzepatide resolved this paradox. The key insight is that GIPR pharmacology in the context of obesity is receptor-context dependent: when hypothalamic GLP-1R are sensitised by concurrent GLP-1R agonism, GIPR co-activation then produces robust central appetite suppression that GIPR agonism alone cannot achieve in a leptin-resistant or GLP-1R-naive hypothalamic environment. In other words, tirzepatide's GIPR component does not merely add incremental insulin secretion — it actively sensitises the hypothalamic GLP-1 axis, amplifying the very pathway that drives the central satiety response. This represents a qualitatively distinct mechanism from simple dual-pathway summation.
Tirzepatide's 39-amino acid sequence is based on the native GIP peptide backbone with selective substitutions that confer GLP-1R binding affinity, metabolic stability, and a C18 fatty diacid moiety at Lys26 for albumin binding. Albumin binding extends the plasma half-life to approximately 5 days, enabling once-weekly subcutaneous dosing — a significant practical advantage over shorter-acting incretin analogues.
SURMOUNT Clinical Trial Data
Tirzepatide has been evaluated across an extensive clinical programme spanning type 2 diabetes (SURPASS series) and obesity without diabetes (SURMOUNT series). The SURMOUNT trials are the pivotal dataset for understanding tirzepatide's weight-reduction profile and represent some of the largest and most rigorous randomised controlled trials conducted in the field of metabolic medicine.
Dose-Titration Protocol
All SURMOUNT trials employed a structured dose-escalation schedule designed to minimise gastrointestinal adverse effects during the initiation phase. Starting at 2.5 mg once weekly, the dose was increased by 2.5 mg increments every four weeks through 5, 7.5, 10, 12.5, and 15 mg — reaching the maintenance dose at approximately week 20. This 20-week titration schedule is an important variable when interpreting early-phase weight-loss data from these trials, as the full pharmacological effect at maintenance dose is not observed until after the escalation period concludes.
| Trial | Population | Primary Outcome | Key Result | Evidence |
|---|---|---|---|---|
| SURMOUNT-1 (2022, NEJM) | Obesity/overweight, no T2D (n = 2539) | % change in body weight at 72 weeks | 10 mg: −19.5%; 15 mg: −20.9%; placebo: −3.1% | Phase III RCT |
| SURMOUNT-3 (2023) | Obesity/overweight following 12-week intensive lifestyle run-in phase | % change in body weight from randomisation baseline | Up to −26.6% from run-in baseline; −18.4% from randomisation | Phase III RCT |
| SURMOUNT-4 (2023) | Responders from open-label lead-in re-randomised to continue or discontinue | Weight regain following discontinuation vs. continuation | Discontinuation group regained ~14% body weight; continuation group lost further 5.5% | Phase III RCT |
| SURPASS-2 (2021, NEJM) | T2D inadequately controlled on metformin (n = 1879) | HbA1c reduction and body weight change vs. semaglutide 1 mg | Tirzepatide 15 mg: −2.46% HbA1c vs. −1.86% sema; weight −11.2 kg vs. −5.7 kg | Active-Controlled RCT |
In SURMOUNT-1, 91% of participants treated with tirzepatide 10 mg and 89% treated with 15 mg achieved ≥5% body weight reduction, compared with 35% on placebo. Furthermore, 57% (10 mg) and 63% (15 mg) of participants achieved ≥20% body weight reduction — a threshold that was previously associated almost exclusively with bariatric surgical procedures. These findings established tirzepatide as the most efficacious approved pharmacological intervention for obesity at time of writing.
SURMOUNT-4 and the Weight-Regain Phenomenon
The SURMOUNT-4 data are mechanistically informative: participants who discontinued tirzepatide after a successful weight-loss phase regained approximately 14% of body weight over the subsequent 52 weeks, while those continuing treatment lost an additional 5.5%. This pattern — mirroring the STEP-4 data for semaglutide — indicates that tirzepatide's efficacy is dependent on continuous receptor engagement. The body's defended adiposity set-point reasserts itself in the absence of ongoing incretin receptor signalling, consistent with the hypothesis that obesity involves a dysregulated neuroendocrine feedback system rather than simply a caloric surplus problem.
Comparison with Semaglutide
Semaglutide (Ozempic®, Wegovy®) is a selective GLP-1 receptor agonist and represents the previous benchmark for pharmacological weight management. Understanding the mechanistic and clinical distinctions between tirzepatide and semaglutide is central to interpreting the GLP-1 receptor agonist literature as a whole. Both compounds share a once-weekly subcutaneous dosing schedule and the same backbone pharmacokinetic strategy of fatty acid conjugation for albumin binding, yet their clinical outcomes differ meaningfully.
Mechanistic Comparison
Semaglutide acts exclusively at the GLP-1 receptor — it has no meaningful affinity for the GIPR. Its weight-loss effects are therefore driven entirely by GLP-1R-mediated pathways: hypothalamic appetite suppression, reduced gastric emptying, and decreased glucagon secretion. Tirzepatide adds three distinct mechanistic contributions that semaglutide lacks: direct GIPR-mediated lipolysis in adipose tissue, GIPR-driven hypothalamic appetite suppression via arcuate nucleus circuits, and the synergistic sensitisation of hypothalamic GLP-1R described above. These additional mechanisms translate into a clinical weight-reduction advantage of approximately 5–6 percentage points at equivalent clinical doses.
| Parameter | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIPR + GLP-1R agonist ("twincretin") | Selective GLP-1R agonist |
| Half-life | ~5 days | ~7 days |
| Max approved dose (obesity) | 15 mg SC once weekly | 2.4 mg SC once weekly (Wegovy®) |
| SURMOUNT-1 / STEP-1 mean weight loss | −20.9% (15 mg, 72 weeks) | −14.9% (2.4 mg, 68 weeks) |
| Head-to-head (SURPASS-2, T2D) | −11.2 kg (15 mg); −2.46% HbA1c | −5.7 kg (1 mg); −1.86% HbA1c |
| Achieving ≥20% weight loss | 63% of participants (15 mg, SURMOUNT-1) | ~32% of participants (2.4 mg, STEP-1) |
| GI adverse events (nausea) | Nausea in ~30–33% (mostly mild-moderate, transient) | Nausea in ~40–44% at max dose |
| Adipose-direct lipolytic effect | Yes (GIPR in adipocytes) | No direct GIPR-mediated pathway |
| Cardiovascular outcomes data | SURPASS-CVOT ongoing at time of writing | SUSTAIN-6 / SELECT: CV risk reduction demonstrated |
SURPASS-2: Direct Head-to-Head Evidence
SURPASS-2 is among the most methodologically significant trials in the incretin pharmacology literature because it provides direct, randomised, head-to-head comparison rather than cross-trial inference. In 1879 adults with T2D inadequately controlled on metformin, tirzepatide at all three doses (5, 10, and 15 mg) demonstrated statistically superior HbA1c reduction compared with semaglutide 1 mg at 40 weeks. The 15 mg dose produced a 5.5 kg greater reduction in body weight (−11.2 kg vs −5.7 kg). Critically, this was achieved against the commercially available once-weekly dose of semaglutide, not the higher 2.4 mg dose used in STEP obesity trials — a distinction that introduces a degree of caveat when extrapolating these comparisons to the obesity population.
Tirzepatide's modestly lower nausea incidence compared with high-dose semaglutide has been tentatively attributed to the GIPR component. In preclinical models, GIPR agonism partially counteracts the gastric motility-slowing effect of GLP-1R activation, potentially attenuating the emetic stimuli that most commonly drive nausea in GLP-1-based therapies. This mechanistic hypothesis is consistent with the clinical observation but has not yet been directly confirmed in human pharmacokinetic-pharmacodynamic studies.
